Education
About Us
Working with TipRanks
Follow Us
Pharming Group Nv (PHAR)
NASDAQ:PHAR
PHAR Stock Chart & Stats
$18.44
>-$0.01(-0.06%)
At close: 4:00 PM EST
$18.44
>-$0.01(-0.06%)
Day’s Range― - ―
52-Week Range$7.50 - $19.05
Previous CloseN/A
Volume11.43K
Average Volume (3M)25.13K
Market Cap
$1.30B
Enterprise Value$968.88M
Total Cash (Recent Filing)$141.54M
Total Debt (Recent Filing)$111.52M
Price to Earnings (P/E)1280.6
Beta0.46
Next Earnings
Mar 12, 2026EPS Estimate
0.02Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.10
Shares Outstanding70,140,400
10 Day Avg. Volume27,532
30 Day Avg. Volume25,130
Financial Highlights & Ratios
PEG Ratio-3.28
Price to Book (P/B)3.03
Price to Sales (P/S)2.26
P/FCF Ratio-258.67
Enterprise Value/Market Cap0.74
Enterprise Value/Revenue2.67
Enterprise Value/Gross Profit2.97
Enterprise Value/Ebitda21.66
Forecast
1Y Price Target
$39.50Price Target Upside114.21% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)0.08
Revenue Forecast (FY)$373.88M
Bulls Say, Bears Say
Bulls Say
Market ExpansionThe global reach and addressable population for leniolisib continue to advance, with recent submissions and launches in markets like Japan and the U.K.
Product ApprovalThe FDA accepted the sNDA seeking approval for leniolisib in children 4-11 years old with APDS, with a PDUFA date set for January 31, 2026.
Revenue GuidanceTotal revenue guidance has been increased from $335-350 million to $365-375 million, reflecting continued growth across the commercial products.
Bears Say
Pharming Group News
PHAR FAQ
What was Pharming Group Nv’s price range in the past 12 months?
Pharming Group Nv lowest stock price was $7.50 and its highest was $19.05 in the past 12 months.
What is Pharming Group Nv’s market cap?
Pharming Group Nv’s market cap is $1.30B.
When is Pharming Group Nv’s upcoming earnings report date?
Pharming Group Nv’s upcoming earnings report date is Mar 12, 2026 which is in 52 days.
How were Pharming Group Nv’s earnings last quarter?
Pharming Group Nv released its earnings results on Nov 06, 2025. The company reported $0.1 earnings per share for the quarter, beating the consensus estimate of $0.004 by $0.096.
Is Pharming Group Nv overvalued?
According to Wall Street analysts Pharming Group Nv’s price is currently Undervalued.
Does Pharming Group Nv pay dividends?
Pharming Group Nv does not currently pay dividends.
What is Pharming Group Nv’s EPS estimate?
Pharming Group Nv’s EPS estimate is 0.02.
How many shares outstanding does Pharming Group Nv have?
Pharming Group Nv has 70,140,400 shares outstanding.
What happened to Pharming Group Nv’s price movement after its last earnings report?
Pharming Group Nv reported an EPS of $0.1 in its last earnings report, beating expectations of $0.004. Following the earnings report the stock price went up 11.533%.
Which hedge fund is a major shareholder of Pharming Group Nv?
Currently, no hedge funds are holding shares in PHAR
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Pharming Group Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$39.50 (114.21% Upside)
$39.50 (114.21% Upside)
Blogger Sentiment
Bullish
PHAR Sentiment 70%
Sector Average ―
Sector Average ―
Crowd Wisdom
Very Positive
Last 7 Days ▼ 1.8%
Last 30 Days ▲ 16.7%
Last 30 Days ▲ 16.7%
Technicals
SMA
Positive
20 days / 200 days
Momentum
93.59%
12-Months-Change
Fundamentals
Return on Equity
0.44%
Trailing 12-Months
Asset Growth
11.34%
Trailing 12-Months
Company Description
Pharming Group Nv
Pharming Group N.V., a biopharmaceutical company, develops and commercialize protein replacement therapies and precision medicines for the treatment of rare diseases and unmet medical needs in the United States, Europe, and internationally. The company's lead product is Ruconest, a recombinant human C1 esterase inhibitor that is used for the treatment of acute hereditary angioedema. It also engages in the development of rhC1INH for the treatment of pre-eclampsia, acute kidney injury, and COVID-19; leniolisib, a phosphoinositide 3-kinase delta (PI3K delta) to treat patients with activated PI3K delta syndrome; and alpha-glucosidase therapy for the treatment of pompe and fabry diseases. The company has a development collaboration and license agreement with Novartis; and a strategic collaboration agreement with Orchard Therapeutics plc for research, development, manufacturing, and commercialization of OTL-105, an investigational ex-vivo autologous hematopoietic stem cell gene therapy for the treatment of hereditary angioedema. Pharming Group N.V. is headquartered in Leiden, the Netherlands.
PHAR Company Deck
PHAR Earnings Call
Q3 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call reflects a strong financial performance with significant revenue growth and an optimistic future outlook. The primary growth drivers, RUCONEST and Joenja, have performed exceptionally well, and the upgraded revenue guidance underscores company confidence. However, challenges exist with the international market withdrawal of RUCONEST and the VUS reclassification timeline. Overall, the positive aspects outweigh the challenges.View all PHAR earnings summariesPHAR Stock 12 Month Forecast
Average Price Target
$39.50
▲(114.21% Upside)
Technical Analysis
Trevi Therapeutics
―
Oric Pharmaceuticals
―
Praxis Precision Medicines
―
ARS Pharmaceuticals
―
Prime Medicine, Inc.
―
Ownership Overview
―
Insiders
<0.01% Mutual Funds
0.07% Other Institutional Investors
99.92% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---